


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5846676/publications.pdf Version: 2024-02-01



Duili

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 2014, 507, 366-370.	13.7	882
3	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nature Medicine, 2021, 27, 1990-2001.	15.2	396
4	Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Science Translational Medicine, 2015, 7, 310ra166.	5.8	334
5	Reassessing B cell contributions in multiple sclerosis. Nature Immunology, 2018, 19, 696-707.	7.0	275
6	Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. Journal of Immunology, 2017, 198, 691-698.	0.4	112
7	Nerve growth factor activates autophagy in Schwann cells to enhance myelin debris clearance and to expedite nerve regeneration. Theranostics, 2020, 10, 1649-1677.	4.6	111
8	Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurology, The, 2021, 20, 470-483.	4.9	96
9	Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β. Journal of Neuroimmunology, 2009, 207, 83-91.	1.1	87
10	B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. Journal of Neuroimmunology, 2017, 309, 88-99.	1.1	85
11	A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e105421.	1.1	81
12	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	1.6	73
13	Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e340.	3.1	73
14	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain, 2019, 142, 617-632.	3.7	72
15	Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 626.	2.2	69
16	Immune-related GTPase M (IRGM1) regulates neuronal autophagy in a mouse model of stroke. Autophagy, 2012, 8, 1621-1627.	4.3	47
17	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. Science Translational Medicine, 2019, 11, .	5.8	45
18	IL-17A and IL-17F Expression in B Lymphocytes. International Archives of Allergy and Immunology, 2012, 157, 406-416.	0.9	37

Rui Li

#	Article	IF	CITATIONS
19	BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. European Journal of Immunology, 2009, 39, 800-809.	1.6	36
20	IFNg-induced Irgm1 promotes tumorigenesis of melanoma via dual regulation of apoptosis and Bif-1-dependent autophagy. Oncogene, 2015, 34, 5363-5371.	2.6	32
21	Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Multiple Sclerosis Journal, 2017, 23, 1225-1232.	1.4	32
22	Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. Journal of Immunology, 2017, 198, 3245-3254.	0.4	31
23	IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis. Scientific Reports, 2013, 3, 1867.	1.6	30
24	BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathologica, 2022, 143, 505-521.	3.9	29
25	Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. Scientific Reports, 2020, 10, 356.	1.6	24
26	Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	21
27	IRGM1 enhances B16 melanoma cell metastasis through PI3K-Rac1 mediated epithelial mesenchymal transition. Scientific Reports, 2015, 5, 12357.	1.6	19
28	Protein methylation functions as the posttranslational modification switch to regulate autophagy. Cellular and Molecular Life Sciences, 2019, 76, 3711-3722.	2.4	18
29	The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029108.	2.9	17
30	lrgm1 is required for the inflammatory function of M1 macrophage in early experimental autoimmune encephalomyelitis. Journal of Leukocyte Biology, 2017, 101, 507-517.	1.5	15
31	Intravenous Administration of Adipose-Derived Stem Cell Protein Extracts Improves Neurological Deficits in a Rat Model of Stroke. Stem Cells International, 2017, 2017, 1-11.	1.2	15
32	lsotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicdaâ~'/â~' and Ungâ~'/â~' Mice. Journal of Immunology, 2018, 201, 1119-1130.	0.4	15
33	Combination of mild therapeutic hypothermia and adipose-derived stem cells for ischemic brain injury. Neural Regeneration Research, 2018, 13, 1759.	1.6	15
34	Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles. Cell Death and Disease, 2021, 12, 392.	2.7	13
35	ILâ€17 Eliminates the Therapeutic Effects of Myelin Basic Proteinâ€Induced Nasal Tolerance in Experimental Autoimmune Encephalomyelitis by Activating ILâ€6. Scandinavian Journal of Immunology, 2008, 68, 589-597.	1.3	11
36	IRGM promotes the PINK1â€mediated mitophagy through the degradation of Mitofilin in SHâ€SY5Y cells. FASEB Journal, 2020, 34, 14768-14779.	0.2	10

Rui Li

#	Article	IF	CITATIONS
37	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	1.4	9
38	Regulation of suppressing and activating effects of mesenchymal stem cells on the encephalitogenic potential of MBP68–86-specific lymphocytes. Journal of Neuroimmunology, 2010, 226, 116-125.	1.1	5
39	Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow). Scientific Reports, 2020, 10, 14823.	1.6	5
40	IRGM promotes melanoma cell survival through autophagy and is a promising prognostic biomarker for clinical application. Molecular Therapy - Oncolytics, 2021, 20, 187-198.	2.0	4
41	Humor in systemic lupus erythematosus. European Journal of Rheumatology, 2015, 2, 5-9.	1.3	3
42	Increased adiponectin levels in serum of early pediatric onset MS induce pro-inflammatory responses of both myeloid cells and T cells. Journal of Neuroimmunology, 2014, 275, 90-91.	1.1	0
43	Abnormal responses of CD8+CD161high mucosal associated invariant T (MAIT) cells and CCR2+CCR5+ CD4 T cells contribute to disrupted balance of effector and regulatory T cells in pediatric-onset MS. Journal of Neuroimmunology, 2014, 275, 203-204.	1.1	0
44	â€~Cytokine defined' B cell subsets in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 10.	1.1	0
45	Human B cell and glial cell interactions: Implications to the compartmentalized CNS inflammation of multiple sclerosis (MS). Journal of Neuroimmunology, 2014, 275, 176-177.	1.1	0
46	Multiple sclerosis meets systems immunology – Authors' reply. Lancet Neurology, The, 2021, 20, 888.	4.9	0